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Abstract
Remodelling of mitochondrial metabolism is a hallmark of cancer. Mutations in the genes encoding
succinate dehydrogenase (SDH), a key Krebs cycle component, are associated with hereditary
predisposition to pheochromocytoma and paraganglioma, through mechanisms which are largely
unknown. Recently, the jumonji-domain histone demethylases have emerged as a novel family of 2-
oxoglutarate-dependent chromatin modifiers with credible functions in tumourigenesis. Using
pharmacological and siRNA methodologies we show that increased methylation of histone H3 is a
general consequence of SDH loss-of-function in cultured mammalian cells and can be reversed by
overexpression of the JMJD3 histone demethylase. ChIP analysis revealed that the core promoter
of IGFBP7, which encodes a secreted protein upregulated after loss of SDHB, showed decreased
occupancy by H3K27me3 in the absence of SDH. Finally, we provide the first evidence that the chief
(type I) cell is the major methylated histone-immunoreactive constituent of paraganglioma. These
results support the notion that loss of mitochondrial function alters epigenetic processes and might
provide a signature methylation mark for paraganglioma.
Findings
Forming part of complex II of the respiratory chain, succi-
nate dehydrogenase (SDH) is situated at the intersection
of the tricarboxylic acid (Krebs) cycle and oxidative phos-
phorylation. This combination of functions places SDH at
the centre of two essential energy-producing metabolic
processes of the cell. Recently, SDH genes have been con-
sidered as tumour suppressors since germ line inactivating
mutations in the SDHB, C and D subunit genes can pre-
dispose individuals to hereditary paraganglioma (HPGL)
[1,2] and phaeochromocytoma [3]. HPGL tumours can be
found in the carotid body, a chemoreceptor organ consist-
ing of several cell types [4]. The most predominant cell
type in the carotid body is the chief (type I) cell; these
cells, of neural crest origin, are arranged in rounded cell
nests. The second prominent cell type is the type II glial-
like (sustentacular) cell, which surrounds the nest of chief
cells. Together, these cells form the striking cell ball of the
paraganglion, traditionally referred to as "zellballen" [5].
Although the mechanism(s) linking SDH deficiency to
tumour formation remain poorly understood, an activa-
tion of the hypoxia pathway is frequently associated with
SDH loss of function [6,7]. This results in the stabilization
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of hypoxia-inducible factor-1 (HIF-1), a broad-range
transcription factor which coordinates cellular adaption
to hypoxia [8]. We recently showed that HIF-1 stabiliza-
tion occurs after chronic silencing of the SDHB gene in
cultured cells [9], and previous studies have demonstrated
that increased cellular succinate, following SDHD silenc-
ing, inhibits the activity of 2-oxoglutarate-dependent pro-
lyl hydroxylases, master regulators of HIF-1 [10].
Increasing intracellular succinate could, however, also
inhibit other 2-oxoglutarate-dependent enzymes, such as
the recently identified histone demethylase family of
chromatin modifiers [11].
The human genome contains ~30 potential histone
demethylases, which are defined by the catalytic jumonji
(JmjC) domain [12]. These JmjC histone demethylases
(JHDMs) catalyse the 2-oxoglutarate-dependent oxida-
tion of methyl groups in the side chains of the basic
amino acids lysine and arginine of histones H3 and H4
[13]. Methylation influences both gene activation and
repression, and the effect on chromatin structure depends
on the degree of methylation and the specific lysine
involved [12]. Histone demethylases are increasingly rec-
ognised as playing important roles in many biological
processes including development [14], metabolism [15],
and cancer [16], and constitute a level of epigenetic con-
trol over and above normal transcriptional processes. In
this present study we determined whether histone modi-
fication was perturbed under conditions of SDH inactiva-
tion.
Cultured cells were exposed to pharmacological suppres-
sion of SDH activity with 2-thenoyltrifluoroacetone
(TTFA). Using Western blot analysis with methylation-
state-specific antibodies, we determined the steady-state
levels of histone 3 methylated on residues K9, K27, and
K36. Addition of TTFA resulted in a reproducible increase
in global histone 3 methylation in Hep3B and HT1080
human cell lines and also in rat PC12 phaeochromocy-
toma cells, although the lysine affected and the degree of
increase was cell line-dependent (Figure 1A and 1B). We
next silenced expression of the endogenous SDHD gene in
cultured cells. Transient silencing of SDHD in HEK293
cells resulted in a significant reduction of SDHD mRNA in
whole cells (Figure 2A). At the same time, analysis of
nuclear histones revealed an increase in steady-state levels
of both H3K27me3 and H3K36me2 upon SDHD silenc-
ing, with H3K36me2 presenting the greatest increase (Fig-
ure 2A). To further validate this response we silenced a
second SDH gene, SDHB. Transient silencing of SDHB in
Hep3B cells resulted in a robust reduction of SDHB pro-
tein as measured by Western blot, and analysis of nuclear
histones showed increased steady-state levels of both
H3K27me3 and H3K36me2 (Figure 2B). Similar results
were obtained after transient silencing of SDHB in the
HEK293 cell line (Figure 2C), confirming the generality of
this response. Moreover, analysis of cells in which SDHB
was chronically silenced by integrated siRNA (cell lines
D11 and D20) [9] revealed a consistent increase in meth-
ylated histone residues (Figure 2D). Given that histone
methylation is a dynamic phenomenon, we wanted to
ensure that the SDH-dependent methylation could be
reversed by increasing demethylase activity. We therefore
forced overexpression of the H3K27me3-specific Jmjd3
histone demethylase [17] in cells. Transfection of an HA-
tagged C-terminal region of Jmjd3, containing the JmjC
domain, but not a mutated (non-active) C-terminal
region was sufficient to downregulate H3K27me3 levels
in Hep3B cells, as shown by double staining with an anti-
HA antibody and the methylation-specific anti-
H3K27me3 antibody (Figure 3A). Consistently, when
overexpressed in the D11 (SDHB-deficient) cell line, wild-
type but not mutated Jmjd3 downregulated H3K27me3
levels (Figure 3B). Together, these data strongly suggest
Pharmacological SDH inhibition increases histone methyla- tion Figure 1
Pharmacological SDH inhibition increases histone 
methylation. (A). Immunoblot analysis of histone methyla-
tion in Hep3B, HT1080 and PC12 cells treated for 24 h with 
500 M 2-thenoyltrifluoroacetone (TTFA). In all cases lanes 
were loaded with 5 g histone extract, and blots were ana-
lysed with the indicated antibodies. Histone H3 total expres-
sion was analysed as a loading control. (B) Densitometric 
analysis of three independent experiments. Fold increase was 
calculated as the ratio of methylated lysine to H3 control, 
between treatments.Molecular Cancer 2009, 8:89 http://www.molecular-cancer.com/content/8/1/89
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that SDH gene inactivation leads to a reversible dysregula-
tion of chromatin remodelling by increasing the global
level of histone H3 methylation.
We attempted to assess a direct relationship between
SDH-induced chromatin alterations and the transcrip-
tional regulation of specific genes. As the full set of genes
potentially regulated by this process is unknown, we
chose three candidate genes, SNCA, PTGER and KRT17,
whose core promoter regions are occupied by H3K27me3,
and which have recently been shown to define an epige-
netic signature of metastatic prostate cancer [18]. Addi-
tionaly, we examined binding at the gene promoter of
insulin-like growth factor binding protein 7 (IGFBP7), a
tumour-related soluble factor whose transcript was highly
upregulated in our microarray analysis of SDHB-deficient
cells [9], and which has been shown to be under epige-
netic control [19]. Chromatin immunoprecipitation
(ChIP) was carried out with anti-H3K27me3 or IgG con-
trol antibody on lysates from control pU6 or SDHB-
silenced D11 cells. Consistent with previous results [19],
subsequent PCR analysis detected H3K27me3 occupancy
of the promoters of SNCA, PTGER and KRT17; however,
there were no apparent differences between control pU6
and the SDHB-deficient D11 cells (Figure 3C). In contrast,
H3K27me3 occupancy of the IGFPB7  promoter was
reduced in D11 compared with pU6 cells (Figure 3C).
This was confirmed by quantitative RT-PCR, giving a fold
difference in site occupancy of 0.625 ± 0.025 (n = 3).
Decreased occupancy would equate to increased tran-
scriptional expression, consistent with our previous
results [9], and provides a positive control for future anal-
ysis.
Tumours of the carotid body and other paraganglia often
retain the general histological pattern of normal paragan-
Succinate dehydrogenase gene inhibition dysregulates histone methylation Figure 2
Succinate dehydrogenase gene inhibition dysregulates histone methylation. (A) HEK293 cells were transfected in 
duplicate with ON-TARGETplus SMARTpool siRNAs targeting SDHD or with a non-targeting control (100 nM) for 72 h. One 
half of the sample was used to prepare RNA and the other half was processed for histone extraction. The silencing efficiency of 
SDHD was analysed by RT-PCR (top panel). Gel lanes were loaded with 5 g histone extract (bottom panel), and immuno blot-
ting carried out with the antibodies indicated. Histone H3 was used as a loading control. Graph shows densitometric analysis of 
two independent experiments. (B) Hep3B cells were transfected in duplicate with ON-TARGETplus SMARTpool siRNAs tar-
geting SDHB or with a non-targeting control (100 nM) for 72 and 96 h. One half of the sample was used to prepare whole cell 
extracts and the other half was processed for histone extraction. Gel lanes were loaded with 20 g total cell extract (top 
panel) or 5 g histone extract (bottom panel), and immuno blotting carried out with the antibodies indicated. Tubulin and his-
tone H3 were analysed as loading controls for whole cell and histone extracts, respectively. Graph shows densitometric analy-
sis of three independent experiments. (C) HEK293 cells were transfected as in (B) and processed for analysis after 96 h. Graph 
shows densitometric analysis of two independent experiments. (D) Immunoblot analysis of wild-type pU6, and SDHB-silenced 
D11 and D20 cell lines. Samples were processed as described above. Graph shows densitometric analysis of three independent 
experiments.Molecular Cancer 2009, 8:89 http://www.molecular-cancer.com/content/8/1/89
Page 4 of 7
(page number not for citation purposes)
glia (Figure 4A). We selected five carotid body paragangli-
omas and assessed the expression and expected staining
pattern of S100, a marker for sustentacular cells and of
tyrosine hydroxylase, a marker for chief cells. All tumours
tested showed the expected positive (brown) staining pat-
tern (exemplified in a sporadic tumour, Figure 4B and
4C). The tumours were then assessed for histone 3 lysine
methylation. As shown in a sporadic paraganglioma
tumour, the chief cell fraction showed strong nuclear
staining for H3K27me3 (Figure 4D, black arrow). Nota-
bly, sustentacular cells (red arrow) showed no nuclear or
cytoplasmic staining. A striking feature of H3K27me3
staining in chief cells was its heterogeneity (Figure 4E,
black arrow). In contrast, the staining pattern for
H3K36me2 was more homogeneous: chief cells showed
predominantly nuclear staining (Figure 4F, black arrow)
with occasional cytoplasmic staining, while sustentacular
cells showed no nuclear staining (Figure 4F, red arrow)
and only light, possibly background, staining of the cyto-
plasm. The staining patterns of both antibodies highlight
the "zellball" structure of the tissue. It should be noted
that all tumours tested (three sporadic paragangliomas
and two SDHD  tumours) showed similar patterns of
staining (not shown). The differential staining of chief cell
nuclei would suggest that these cells represent the tran-
Functional consequences of increased histone methylation in  SDHB-silenced cells Figure 3
Functional consequences of increased histone meth-
ylation in SDHB-silenced cells. (A) Confocal images of 
SDHB-silenced D11 cells transiently transfected with the 
overexpression plasmids JMJD3 (wildtype) or JMJD3 mutated 
(mutant). At 72 h post transfection, cells were fixed and 
stained with anti-HA and anti-H3K27me3 antibodies; nuclei 
were stained with DAPI. Arrows indicate transfected cells. (B) 
Immunoblot analysis of cell lines pU6 and D11, transiently 
transfected for 72 h with pcDNA control (vec), JMJD3 wild-
type (wt) or JMJD3 mutated (mut). Results are representa-
tive from two independent experiments. (C) ChIP analysis of 
H3K27me3 occupancy of the core promoter regions of 
IGFBP7, SNCA, PTGER, and KRT17 in pU6 and D11 cells. Gels 
show representative RT-PCR analysis of H3K27me3 and 
control IgG immunoprecipitates.
Immunohistochemical staining for methylated histones in a  sporadic carotid body paraganglioma Figure 4
Immunohistochemical staining for methylated his-
tones in a sporadic carotid body paraganglioma. (A) 
Haematoxylin-eosin staining of a sporadic paraganglioma 
(100× magnification) showing typical cell nest structure. (B) 
Nuclear and cytoplasmic staining of sustentacular cells using 
an antibody directed to S100 (400×). Brown staining high-
lights the typical zellballen structures. (C) Nuclear staining of 
chief (type I) cells with the tyrosine hydroxylase marker anti-
body (400×). (D) Anti-H3K27me3 staining (400× with digital 
enlargement). A clear zellballen structure is visible, showing 
exclusively nuclear staining of chief cells (dark arrow) but no 
staining of sustentacular cells (red arrow). (E) High-magnifica-
tion image of anti-H3K27me3 staining showing heterogene-
ous nuclear staining of chief cells (arrow). (F) Anti-
H3K36me2 staining (400×). There is nuclear and some cyto-
plasmic staining of chief cells (dark arrow) but no nuclear 
staining of sustentacular cells (red arrow) and only light 
(background) staining of the cytoplasm. This specific staining 
pattern again highlights the zellballen structures. In all cases a 
sporadic tumour is illustrated, chosen for clarity. SDHD 
tumours show similar patterns of staining.Molecular Cancer 2009, 8:89 http://www.molecular-cancer.com/content/8/1/89
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scriptionally active component of the paraganglioma. The
heterogeneous staining pattern for H3K27me3 in the
chief cells is reminiscent of the ultrastructural studies of
Grimely and Glenner [20], in which they describe "light"
and "dark" chief cells. No specific function has ever been
attributed to these two forms, and they may indeed sim-
ply be transitory forms of the same cell.
In the present study we have shown that metabolic pertur-
bations within the mitochondrial SDH complex result in
a reversible dysregulation of post-translational histone
methylation, leading to increased steady-state levels of
methylated lysine on histone H3. Product inhibition of
the demethylation reaction with succinate is the most
likely cause of this dysregulation. The above scenario
would predict a non-discriminatory decrease in total cel-
lular demethylase activity following SDH inhibition,
orchestrated perhaps by different succinate Ki values for
individual demethylases. It is evident that further studies
would benefit from genome-wide location analysis
(ChIP-on-chip) to survey the underlying chromatin envi-
ronment associated with SDH dysfunction. As an overture
to this analysis, we used ChIP to measure H3K27me3
occupancy at four independent loci, detecting reduced
occupancy at the IGFBP7  promoter in SDHB-deficient
cells. Interestingly, recent studies have described the co-
existence of H3K4 and H3K27 methylation marks, a so-
called bivalent domain, on a subset of developmentally
regulated loci in embryonic stem cells [21]. This differ-
ence in occupancy between methylated H3K4 and H3K27
could therefore direct increased or decreased transcrip-
tional expression, and provides a plausible explanation
for our observations. Of note this study highlights the
type I chief cell as the principal immunoreactive cell type
for both H3K27me3 and H3K36me2 in the carotid body
tumours tested. It would be interesting to see whether all
SDH-related tumours show similar staining patterns.
Chief cells are the master chemosensory cells of the
carotid body and are physiologically complex [22]. Con-
versely, type II cells lack most of these actions and are gen-
erally thought to provide a supporting role to chief cells.
Consistent with this notion, multiparameter DNA flow
cytometry analysis of SDHD-related tumours indicates
that chief cells are the neoplastic component of paragang-
liomas [23]: utilizing S-100 labelling as a selective marker
for the sustentacular fraction, this study showed that S-
100-labelled cells are diploid, and show retention of the
wild-type allele, while loss of the wild-type allele was seen
in the S-100-negative fraction. Therefore type II cells can
be seen as a non-neoplastic cell population induced as a
tumour-specific stromal component of the chief cells.
In summary our initial results demonstrate an epigenetic
operation linked to SDH inhibition in mammalian cells,
and could provide a paradigm for the investigation of epi-
genetic processes that may contribute to tumour predispo-
sition in neuroendocrine neoplasia.
Materials and methods
Cell culture and transfection
Culture media, fetal bovine serum, and Lipofectamine™
2000 were from Invitrogen Life Technologies (Carlsbad,
CA). All remaining chemicals, unless otherwise stated,
were from Sigma Chemical Co. (Poole, UK). Hep3B cells
(including cell lines pU6, D11, and D20) were grown in
modified Eagle's medium containing 10% FBS, 2 mM L-
glutamine, non-essential amino acids, and 1 mM sodium
pyruvate. HEK293 cells were maintained in Dulbecco's
modified Eagle's medium (DMEM) with 10% FBS and 2
mM sodium pyruvate. Rat phaeochromocytoma PC12
cells were grown in DMEM plus 10% horse serum, 5% FBS
and 2 mM L-glutamine. For transient silencing of SDHB
and  SDHD, we used Dharmacon ON-TARGETplus
SMARTpool  siRNA reagents (Thermo Fisher Scientific,
Lafayette, CO): catalogue # L-011771-00 targets SDHB
(NM_003000), catalogue # L-006305-00 targets SDHD
(NM_003002), and catalogue # D-001810-10-05 is a
non-targeting negative control. Cells were transfected
with siRNAs (100 nM) using Lipofectamine and were
processed for analysis as shown in figure legends. Overex-
pression plasmids encoding the C-terminal functional
domain (aa 1141-1641) of the human JMJD3 gene and
also a non-functional mutant (His 1388>Ala) were kind
gifts from Prof. Gioacchino Natoli (European Institute of
Oncology, Milan).
RNA extraction, chromatin immunoprecipitation and RT-
PCR
Total RNA was isolated from cells harvested from t-25 cm2
culture flasks using the RNeasy Mini kit from Qiagen
(Valencia, CA). Total cellular RNA (1 g) was reverse tran-
scribed with 100 Units of Superscript™ II reverse tran-
scriptase (Invitrogen), using oligo-dT primer according to
the manufacturer's instructions. Semi-quantitative PCR
was then performed using specific oligonucleotide prim-
ers for SDHD [11] and cyclophilin [10]. Chromatin immu-
noprecipitation was performed using the ChiP kit (Abcam
Cambridge, UK), following the protocols provided. Frag-
mentation of chromatin to >300 bp was verified by elec-
trophoresis. Immunoprecipitated DNA was analysed by
PCR using oligonucleotide primers to the promoter
regions of the following genes [18]: PTGER3  (GGAT-
GGTTGGAGGCTTTGTA and CAGGAAGGTGGCAT-
CAATTT);  SNCA  (GCTGATTGGTGGAAAGGAAA and
CACGGTCACAGGTTACAACG) and KRT17 (TTGGGGTA-
CAGAAGGGTGAG and TCCCCAGGTTTACACTCCAG).
The core promoter region of the IGFBP7 gene was ana-
lysed using the primers CCCGAGAGGCTTGCTGGAG and
AGGCCTGCTGTGGTCTTGGGTGTC, designed using
PrimerSelect software (DNAStar, Madison, WI).Molecular Cancer 2009, 8:89 http://www.molecular-cancer.com/content/8/1/89
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Western blotting, confocal analysis and 
immunohistochemistry
Preparation of total protein extracts, electrophoresis and
membrane transfer were carried out as described [10].
Total histone fractions were prepared using a standard
extraction protocol (Abcam). Primary antibodies for
immunoblot analysis were purchased as follows: SDHB
(Molecular Probes, Invitrogen), -tubulin (Sigma), H3
and H3K9me3 (Abcam), H3K36me2 and H3K27me3
(Upstate Biotechnology, now Millipore). Protein bands
were detected with species-specific peroxidase-conjugated
antibodies using the enhanced chemiluminescence
method from GE Life Sciences (Piscataway, NJ). For con-
focal analysis, overexpression constructs were detected
using an antibody to the HA peptide (Abcam). Archival
formalin-fixed, paraffin embedded paragangliomas (3×
sporadic, 1× SDHD D92Y, and 1× SDHD L139P) were sec-
tioned at 4 m, and stained with haematoxylin-eosin
according to standard protocols, to assess morphology.
Further sections were boiled in citrate-buffer pH 6.0 for 10
minutes to retrieve antigens, followed by blocking of
endogenous peroxidase activity with hydrogen peroxide,
and then used for immunohistochemistry. Sections were
incubated overnight (o/n) with an antibody specific for
tyrosine hydroxylase (TH) (P40101-0, PelFreez, Arkansas,
USA) at 1:500 dilution. After washes, anti-rabbit horse-
radish peroxidase (HRP) (P0217, Dako, Glostrup, Den-
mark) secondary antibody was applied for 30 min. The
S100 antibody (Z0311, DakoCytomation, Glostrup, Den-
mark) was used o/n diluted 1:100 in PBS/1% BSA, fol-
lowed by anti-rabbit HRP (P0217, Dako) for 30 min. An
antibody against tri-methylated histone 3 lysine 27
(H3K27me3: ab6002, Abcam) was used o/n diluted 1:50
in PBS/1% BSA, followed by anti-mouse HRP secondary
antibody (P0260, Dako) for 30 min. Anti-H3K36me2
antibody (Q16695, Millipore, Amsterdam, Netherlands)
was used o/n diluted 1:100 in PBS/1% BSA, followed by
anti-rabbit HRP (P0217, Dako) for 30 min. The chromog-
enic substrate for all secondary antibodies was DAB
(K3465, Dako). Sections were further processed by stand-
ard techniques.
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